1. Introduction {#sec1}
===============

Extended-spectrum beta-lactamases (ESBL) are enzymes responsible for the hydrolysis of oxyimino-beta-lactam antibiotics, which are important therapeutic agents for the treatment of serious human and animal infections. ESBL were first described in 1983 in Enterobacteriaceae (new taxonomy *Enterobacterales*) and since then, with the research of the scientific community, it has been observed that ESBL-producing Enterobacteriaceae (E-ESBL) are a real threat to human health, being responsible for 1700 deaths in the USA due to therapeutic failure in severe infections in 2013 ([@bib6]; [@bib31]; [@bib118]). However, E-ESBL are not only limited to hospital environment, they are also present as human intestinal commensals ([@bib81]; [@bib112]). The presence of E-ESBL in several ecological niches, as commensals in humans and animals and as environmental contaminants, is reported worldwide, however, in the last decades a niche that has raised great concern, for being able to function as a reservoir and vehicle of transmission and dissemination of E-ESBL is the production animals due to their direct connection with the food chain ([@bib133]).

Cattle are one of the main sources of animal protein, becoming one of the most consumed meat around the world and milk, one of the main constituents of the human food chain ([@bib10]). It is also one of the main sources of biological fertilizers, due to the high production of faecal mass of these animals ([@bib195]). All this, highlights the importance of cattle production in the context of the food chain and the contaminated environment as reservoir and transmitting/disseminating vehicle of E-ESBL, thus configuring a threat to the world public health. This circulation of E-ESBL within our ecosystem creates a consensual concern of the scientific community and of the authority involved in the One health approach ([@bib179]).

The ESBL are enzymes that are classified in several types, being CTX-M, SHV and TEM the most prevalent around the world ([@bib164]). However, there are other ESBL such as OXA, PER, VEB, BES, GES, SFO, TLA, and IBC ([@bib164]). The CTX-M are enzymes with environmental origins which are currently the most widespread type of ESBL and are commonly associated with E-ESBL reports ([@bib29]). Variants such as CTX-M-15, responsible for infectious outbreaks around the world, are associated with a clone responsible for extraintestinal *E. coli* infections resistant to antibiotics, the ST131 ([@bib173]).

The objective of this study was to make an insight about the epidemiology of the spread of E-ESBL and the ESBL genes distribution in cattle around the world, in order to update the current scenario of E-ESBL dissemination through cattle production in all continents.

2. ESBL producing *Enterobacteriaceae* in cattle - a global view {#sec2}
================================================================

The first description of an E-ESBL in cattle was in Japan, where a CTX-M-2 *E. coli* producer was detected in cattle faeces from an important region close to the centre of the country ([@bib192]). From the first description to the present, E-ESBL has already been described in cattle production in 39 countries, with more concentration in Europe (n = 16) and Asia (n = 13) as shown in [Figure 1](#fig1){ref-type="fig"}. The origins of E-ESBL are diverse, being isolated from healthy animals (faecal samples) or from veterinary clinical origin (mastitis, diarrheal processes, infections or with any other pathological picture). The countries with the highest reports on E-ESBL in cattle, are the United Kingdom (n = 14), Germany (n = 11), France (n = 9) and the United States (n = 9), the last one being the world\'s largest cattle producer, and the 3 Europeans, 4^th^, 3^rd^ and 1^st^, respectively, in number of cattle in Europe ([@bib61]; [@bib214]). Within the 5 world largest cattle producers (United States, Brazil, the European Union, China and India) there have been reports of animals harbouring commensal or clinical E-ESBL. The [Table 1](#tbl1){ref-type="table"} shows all the descriptions of E-ESBL in cattle around the World, including the source, species and ESBL gene.Figure 1World map illustrating the countries with description of E-ESBL in cattle.Figure 1Table 1Relation of ESBL described in cattle by type of ESBL, described species, country of report, origin of the isolate and bibliographic reference of the description.Table 1Beta-lactamase*Enterobacteriaceae*CountrySourceReference**CTX-M-1***Escherichia coli***Europe**GermanyFaecal([@bib221])Mastitis([@bib68]; [@bib138])Diarrheic([@bib63])Sick([@bib138])Infection([@bib25])DenmarkCommensal([@bib116])ND([@bib71]; [@bib2])SpainMastitis([@bib26])FinlandFaecal([@bib161])FranceFaecal([@bib85]; [@bib88]; [@bib131]; [@bib137])Mastitis([@bib42])Diarrheic([@bib88])Sick([@bib131]; [@bib217])Infection([@bib137])HungaryInfection([@bib212])PortugalFaecal([@bib174])MayotteND([@bib72])NetherlandsFaecal([@bib32]; [@bib96]; [@bib102], [@bib103], [@bib104])United KingdomFaecal([@bib218])Infection([@bib107])ND([@bib199])Czech RepublicFaecal([@bib52])Sick([@bib53])RéunionND([@bib72])SlovakiaFaecal([@bib117])SwedenFaecal([@bib57])SwitzerlandFaecal([@bib60]; [@bib75]; [@bib232])TurkeyFaecal([@bib14]; [@bib165])**North America**CanadaND([@bib39])USAFaecal([@bib139]; [@bib141]; [@bib222])**Asia**ChinaMastitis([@bib11], [@bib12])South KoreaMastitis([@bib206])IndonesiaFaecal([@bib202])JapanMastitis([@bib154])*Klebsiella pneumoniae***Europe**ItalyMastitis([@bib127])*Klebsiella ozaenae*ItalyFaecal([@bib198])*Salmonella enterica*GermanyND([@bib180])**CTX-M-1/61***E. coli***Europe**GermanyFaecal([@bib43])**CTX-M-2***E. coli***South America**BrazilFaecal([@bib162])**Europe**GermanyMastitis([@bib59]; [@bib68]; [@bib138])Sick([@bib138])NetherlandsFaecal([@bib32]; [@bib96])**North America**CanadaFaecal([@bib38])**Asia**JapanFaecal([@bib192])Diarrheic([@bib153])Infection([@bib13])*K. pneumoniae*JapanMastitis([@bib153], [@bib154]; [@bib184])*Klebsiella oxytoca*JapanMastitis([@bib154])*Citrobacter freundii*JapanMastitis([@bib153])*Citrobacter koseri*JapanMastitis([@bib154])*Enterobacter cloacae*JapanMastitis([@bib153])*Enterobacter aerogenes*JapanMastitis([@bib154])**CTX-M-2/97***E. coli***Europe**NetherlandsFaecal([@bib102], [@bib103], [@bib104])**CTX-M-3***E. coli***Europe**GermanyMastitis([@bib138])FranceFaecal([@bib85])NetherlandsFaecal([@bib32]; [@bib103])United KingdomInfection([@bib107])TurkeyFaecal([@bib14]; [@bib165])**Asia**ChinaFaecal([@bib229])Mastitis([@bib11], [@bib12])South KoreaMastitis([@bib206])Hong KongFaecal([@bib100])**CTX-M-8***E. coli***Europe**NetherlandsFaecal([@bib32])**CTX-M-9***E. coli***Europe**NetherlandsFaecal([@bib32])**North America**USAFaecal([@bib172])**Asia**IndonesiaFaecal([@bib202])**Africa**EgyptFaecal([@bib24])**Oceania**AustraliaSick([@bib5])*S. enteric*AustraliaND([@bib197])**CTX-M-14***E. coli***Europe**GermanyMastitis([@bib59]; [@bib68]; [@bib138])Sick([@bib138])BelgiumFaecal([@bib163])Infection([@bib163])FranceFaecal([@bib85]; [@bib131])Mastitis([@bib42])Sick([@bib131])WalesSick([@bib213])NetherlandsFaecal([@bib32]; [@bib96]; [@bib102], [@bib103], [@bib104])United KingdomFaecal([@bib40]; [@bib105]; [@bib175]; [@bib196])Infection([@bib107])ND([@bib199]; [@bib200])SwitzerlandFaecal([@bib75]; [@bib232])Mastitis([@bib75])**Asia**ChinaFaecal([@bib228], [@bib229])Mastitis([@bib11], [@bib12])South KoreaFaecal([@bib176]; [@bib204])Sick([@bib126])Hong KongFaecal([@bib98], [@bib100])JapanMastitis([@bib154])Diarrheic([@bib153])TaiwanMastitis([@bib201])**North America**CanadaND([@bib39])USAFaecal([@bib141])**Oceania**AustraliaSick([@bib5])*K. pneumoniae***Europe**FranceMastitis([@bib42])**Asia**JapanMastitis([@bib154])**CTX-M-15***E. coli***South America**BrazilFaecal([@bib188])**Europe**GermanyFaecal([@bib66]; [@bib221])Mastitis([@bib59]; [@bib68]; [@bib138])Sick([@bib138])FranceFaecal([@bib85])Sick([@bib131])Infection([@bib132]; [@bib137])MadagascarND([@bib72])MayotteND([@bib72])NetherlandsFaecal([@bib32]; [@bib96]; [@bib102], [@bib103], [@bib104])United KingdomFaecal([@bib105]; [@bib175]; [@bib220])Mastitis([@bib211])Infection([@bib107])SwedenFaecal([@bib57])SwitzerlandFaecal([@bib60]; [@bib75]; [@bib232])TurkeyFaecal([@bib14]; [@bib165])**Asia**ChinaFaecal([@bib229])Mastitis([@bib11], [@bib12])IsraelND([@bib125])South KoreaFaecal([@bib204])Mastitis([@bib206])JapanFaecal([@bib215])Mastitis([@bib154])Diarrheic([@bib153])LebanonFaecal([@bib50])TaiwanMastitis([@bib201])**North America**CanadaND([@bib39])Faecal([@bib38])USAFaecal([@bib139]; [@bib141])**Africa**EgyptFaecal([@bib24])TanzaniaFaecal([@bib190])TunisiaFaecal([@bib82])Mastitis([@bib183])*K. pneumoniae***Europe**FranceFaecal([@bib85])**Asia**IndiaMastitis([@bib119])*K. ozaenae***Europe**ItalyFaecal([@bib198])*K. oxytoca***Asia**EgyptMastitis([@bib9])**CTX-M-15/28***E. coli***Europe**United KingdomFaecal([@bib196])**CTX-M-17***E. coli***Asia**ChinaFaecal([@bib229])**CTX-M-17/18***E. coli***Europe**United KingdomFaecal([@bib124])**CTX-M-20***E. coli***Europe**United KingdomInfection([@bib107])**CTX-M-22***E. coli***Europe**NetherlandsFaecal([@bib96])**CTX-M-24***E. coli***North America**CanadaFaecal([@bib38])**CTX-M-27***E. coli***Europe**NetherlandsFaecal([@bib32])**North America**USAFaecal([@bib203])ND([@bib8])CanadaFaecal([@bib38])ND([@bib39])**CTX-M-28***E. coli***Asia**Hong KongFaecal([@bib98])**CTX-M-32***E. coli***Europe**FranceFaecal([@bib85])GermanyMastitis([@bib59])MayotteND([@bib72])NetherlandsFaecal([@bib32]; [@bib96]; [@bib102], [@bib103], [@bib104])PortugalFaecal([@bib174])United KingdomInfection([@bib107])**North America**CanadaFaecal([@bib38])ND([@bib39])USAFaecal([@bib41]; [@bib172])**Asia**South KoreaFaecal([@bib204])**CTX-M-55***E. coli***Europe**FranceSick([@bib86]; [@bib128])NetherlandsFaecal([@bib32]; [@bib96])SpainFaecal([@bib95])**North America**CanadaFaecal([@bib38])ND([@bib39])**Asia**ChinaFaecal([@bib228], [@bib229])Mastitis([@bib11], [@bib12])Hong KongFaecal([@bib98], [@bib100])TaiwanMastitis([@bib201])**CTX-M-57***E. coli***Europe**FranceFaecal([@bib85])**CTX-M-61***E. coli***North America**CanadaFaecal([@bib38])**CTX-M-63***K. pneumoniae***Asia**IndiaMastitis([@bib119])**CTX-M-65***E. coli***Europe**NetherlandsFaecal([@bib32]; [@bib96])**North America**CanadaFaecal([@bib38])ND([@bib39])*S. enterica*USAND([@bib208])**CTX-M-79***E. coli***Europe**NetherlandsFaecal([@bib104])**North America**USAFaecal([@bib222])**CTX-M-98***E. coli***Asia**Hong KongFaecal([@bib98])**CTX-M-115***E. coli***North America**CanadaFaecal([@bib38])**CTX-M-117***E. coli***Europe**SwitzerlandFaecal([@bib1]; [@bib232])**CTX-M-123***E. coli***Asia**Hong KongFaecal([@bib101])**CTX-M-132***E. coli***Asia**Hong KongFaecal([@bib101])**CTX-M-172***E. coli***North America**CanadaFaecal([@bib38])**CTX-M -- without variant description***E. coli***Europe**GermanyFaecal([@bib224])FranceDiarrheic([@bib216])NetherlandsFaecal([@bib224])United KingdomFaecal([@bib224])SwitzerlandFaecal([@bib74])**North America**CanadaFaecal([@bib15])USAFaecal([@bib45])**Asia**ChinaMastitis([@bib226])Saudi ArabiaND([@bib91])South KoreaFaecal([@bib205])Hong KongFaecal([@bib56])IndiaFaecal([@bib22])Mastitis([@bib18]; [@bib77]; [@bib111])IsraelFaecal([@bib7])MalaysiaFaecal([@bib110])**Africa**South AfricaFaecal([@bib109])NigeriaFaecal([@bib156])*K. pneumoniae***South America**BrazilMastitis([@bib150])**Asia**IndiaMastitis([@bib44])*Salmonella sp***North America**USASick([@bib70])**SHV-2***E. coli***North America**CanadaFaecal([@bib38])**SHV-5***E. coli***Europe**TurkeyFaecal([@bib120])*C. freundii*TurkeyFaecal([@bib120])*C. brakii*TurkeyFaecal([@bib120])**SHV-11***E. coli***Asia**JapanDiarrheic([@bib153])*K. pneumoniae*JapanDiarrheic([@bib153])**SHV-12***E. coli***Europe**GermanySick([@bib138])FranceFaecal([@bib85]; [@bib131])NetherlandsFaecal([@bib32]; [@bib104])TurkeyFaecal([@bib120]; [@bib165])**Asia**ChinaMastitis([@bib11], [@bib12])*K. pneumoniae***Europe**FranceFaecal([@bib85])United KingdomMastitis([@bib211])**Africa**EgyptMastitis([@bib9])*K. oxytoca*EgyptMastitis([@bib9])*E. cloacae*EgyptMastitis([@bib9])**SHV-28***Serratia marcescens***Africa**EgyptMastitis([@bib9])**SHV-180***K. pneumoniae***Asia**IndiaMastitis([@bib119])**SHV -- without variant description***E. coli***Europe**NetherlandsFaecal([@bib224])**Asia**IndiaFaecal([@bib22])Mastitis([@bib111])IsraelFaecal([@bib7])*K. pneumoniae***South America**BrazilMastitis([@bib150])*Salmonella* spp.**North America**USASick([@bib70])**TEM-20***E. coli***Europe**NetherlandsFaecal([@bib104])**TEM-24***K. ozaenae***Europe**ItalyFaecal([@bib198])**TEM-52***E. coli***Europe**GermanyFaecal([@bib221])Sick([@bib138])FranceDiarrheic([@bib84])NetherlandsFaecal([@bib32]; [@bib96]; [@bib102], [@bib103], [@bib104])**TEM-71***E. coli***Europe**FranceFaecal([@bib88])Diarrheic([@bib88])**TEM-126***E. coli***Europe**FranceSick([@bib131])**TEM-186***E. coli***Europe**SwitzerlandFaecal([@bib75])**TEM-190***E. coli***Europe**NetherlandsFaecal([@bib32])**TEM -- without variant description***E. coli***North America**USAFaecal([@bib54]; [@bib139])**Asia**IndiaFaecal([@bib22])ThailandMastitis([@bib97])**Africa**EgyptFaecal([@bib24])**OXA-10***E. coli***Europe**TurkeyFaecal([@bib120])*C. freundii*TurkeyFaecal([@bib120])*C. brakii*TurkeyFaecal([@bib120])**OXA-30***K. oxytoca***Africa**EgyptMastitis([@bib9])*E. cloacae*EgyptMastitis([@bib9])**ESBL producers - without beta-lactamase description (ND-ESBL***E. coli***South America**BrazilMastitis([@bib187])ChileMastitis([@bib80])PeruFaecal([@bib136])**Europe**GermanyFaecal([@bib69])SpainFaecal([@bib26])País de GalesND([@bib209])NetherlandsFaecal([@bib79])SwitzerlandFaecal([@bib177])**North America**CanadaFaecal([@bib129])**Asia**IranFaecal([@bib19])ThailandMastitis([@bib97])**Africa**NigeriaFaecal([@bib152])TanzaniaFaecal([@bib140])*K. pneumoniae***Asia**IsraelFaecal([@bib7])*Klebsiella* spp.**Africa**NigeriaFaecal([@bib152])*Salmonella* spp.NigeriaFaecal([@bib152])*C. youngae***Europe**SwitzerlandFaecal([@bib177])*E. cloacae***South America**PeruFaecal([@bib136])**Europe**SwitzerlandFaecal([@bib177])*Proteus mirabilis***Africa**NigeriaFaecal([@bib152])*Proteus vulgaris*NigeriaFaecal([@bib152])*Providencia* spp.NigeriaFaecal([@bib152])*Shigella* spp.NigeriaFaecal([@bib152])[^2]

The most frequent ESBL types in E-ESBL in cattle, as expected, were the ones of CTX-M-1 group with higher prevalence for CTX-M-1, CTX-M-14 and CTX-M-15. CTX-M-1 was reported in 20 countries, most frequently in Europe (n = 14), being found in Germany, Denmark, Spain, Finland, France, Hungary, Portugal, Netherlands, United Kingdom, Czech Republic, Slovakia, Sweden, Switzerland and Turkey. CTX-M-1 was first described in human E-ESBL in 1989 in Germany, and it has also been reported in other European countries such as Spain, France, Italy and United Kingdom as well as in Asia and North America ([@bib30]; [@bib142]; [@bib219]).

CTX-M-15 and CTX-M-14 are the most important CTX-M enzymes due to their large diffusion and relation to outbreaks and severe extraintestinal infections ([@bib29]; [@bib135]; [@bib173]). CTX-M-14 was described in E-ESBL in cattle in 13 countries, mainly in Europe (Germany, Belgium, France, Netherlands, United Kingdom, and Switzerland) and in Asia (China, South Korea, Hong Kong, Japan, and Taiwan), as well as the United States and Oceania. CTX-M-14 was first described in 2002 in E-ESBL from a hospital in China ([@bib33]; [@bib130]). E-ESBL producers isolated from human of CTX-M-14 type are described in Europe, Asia, North and South America, Africa and Oceania, many times related to pandemic clones such as *E. coli* ST131 responsible for outbreaks in the last years ([@bib28]; [@bib34]; [@bib78]; [@bib166], [@bib167]; [@bib169]; [@bib191]; [@bib194]; [@bib231]).

CTX-M-15 was first described in 2001 in E-ESBL isolate in a hospital in New Delhi, India, and today is the most widespread ESBL in the various niches and the most important of all, due to its high relation to important, for human health, E-ESBL clones ([@bib29]; [@bib36]; [@bib113]; [@bib114]; [@bib173]; [@bib223]). E-ESBL producing CTX-M-15 in cattle were described in 21 countries around the world, present in most of Europe, being reported in Germany, France, Italy, Netherlands, United Kingdom, Sweden, Switzerland and Turkey. In Asia they were described in China, South Korea, India, Israel, Japan, Lebanon and Taiwan and also reported in North and South America (Brazil, Canada and United States) and Africa (Egypt, Tanzania and Tunisia).

CTX-M-15 has been reported in all continents (Europe, North America, South America, Asia, Africa, Oceania and Antarctica with reports in all major ecological niches (humans, animals, and environment), these E-ESBL producers of CTX-M-15 are an excellent example of the public health threat that involves circulation of resistant Enterobacteriaceae and resistance genes among the different ecological niches that is currently evidenced under the prism of the "One Health" approach ([@bib34]; [@bib49]; [@bib64]; [@bib89]; [@bib93]; [@bib123]; [@bib171]; [@bib182]; [@bib193]).

The virulent and multi-resistant CTX-M-15-producing *E. coli* O25b-ST131 clone is certainly one of the most well adapted circulant clones among E-ESBL, which is responsible for outbreaks and deaths around the world and is not related only to infectious processes, but is also reported in human intestinal colonization (elderly, adults and children) and animals (terrestrial and aquatic) and environmental contamination ([@bib16]; [@bib23]; [@bib51]; [@bib62]; [@bib81]; [@bib147]; [@bib148]; [@bib155]; [@bib157]; [@bib160]; [@bib230]).

3. Europe {#sec3}
=========

Europe is the continent with more number of countries (n = 16) with description of E-ESBL in cattle, [Figure 2](#fig2){ref-type="fig"} shows all countries. Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Portugal, Slovakia, Spain, Sweden, Switzerland, Turkey and United Kingdom, presented at least one report of E-ESBL in cattle ([@bib14]; [@bib26]; [@bib52]; [@bib57]; [@bib104]; [@bib107]; [@bib116]; [@bib117]; [@bib138]; [@bib161]; [@bib163]; [@bib174]; [@bib198]; [@bib212]; [@bib217]; [@bib232]). CTX-M-1 was described in 14 of the 16 countries with E-ESBL in cattle, CTX-M-15 present in 7, CTX-M-14 in 6 and CTX-M-3 and SHV-12 in 5 ([@bib14]; [@bib26]; [@bib52]; [@bib57]; [@bib72]; [@bib85]; [@bib103]; [@bib104]; [@bib107]; [@bib116]; [@bib117]; [@bib138]; [@bib161]; [@bib163]; [@bib165]; [@bib174]; [@bib211]; [@bib212]; [@bib217]; [@bib232]).Figure 2Illustrative map of Europe showing countries with description of E-ESBL in cattle and beta-lactamases type.Figure 2

Germany presented the description of CTX-M-1, CTX-M-1/61, CTX-M-2, CTX-M-3, CTX-M-14, CTX-M-15, CTX-M without the variant description (CTX-M), SHV-12, TEM-52 and E-ESBL without the description or detection of beta-lactamase (ND-ESBL) described in *E. coli* and *Salmonella* enterica from faecal and clinical samples ([@bib43]; [@bib69]; [@bib138]; [@bib221]; [@bib224]). CTX-M-1, CTX-M-3, CTX-M-14, CTX-M-15 and SHV-12 have already been reported in E-ESBL in humans in Germany associated with infections ([@bib73]; [@bib144]; [@bib189]).

The Netherlands, German neighbours, also presented high diversity and number of reports of E-ESBL in cattle. There were identified CTX-M-1, CTX-M-2, CTX-M-2/97, CTX-M-3, CTX-M-8, CTX-M-9, CTX-M-14, CTX-M-15, CTX-M-22, CTX-M-27, CTX-M-32, CTX-M-55, CTX-M-65, CTX-M-79, CTX-M, SHV-12, SHV without description of variant (SHV), TEM-20, TEM-52, TEM-190 and ND-ESBL, all of them described in faecal *E. coli*. CTX-M-1, CTX-M-2, CTX-M-14, CTX-M-15, SHV-12 and TEM-52 have already been described in E-ESBL of human (faecal and hospital) origin in the Netherlands ([@bib146]; [@bib159]).

The biggest European cattle producer, France, including 2 French departments in Africa (Mayotte and Réunion) has reported E-ESBL in cattle with CTX-M-1, CTX-M-3, CTX-M-14, CTX-M-15, CTX-M-32, CTX-M-55, CTX-M-57, CTX-M, SHV-12, TEM-52, TEM-71 and TEM-126 reported in *E. coli* and *K. pneumoniae* of faecal and clinical origin. All of the described beta-lactamases (CTX-M-1, CTX-M-3, CTX-M-14, CTX-M-15, CTX-M-32, CTX-M-57, SHV-12, TEM-52, TEM-71 and TEM-126) in cattle have been reported in E-ESBL from humans of hospital origin in France ([@bib46]; [@bib178]).

The United Kingdom was the European country with the highest number of reported CTX-M variants. The CTX-M-1, CTX-M-3, CTX-M-14, CTX-M-15, CTX-M-15/28, CTX-M-17/18, CTX -M-20, CTX-M-32, CTX-M, SHV-12 and ND-ESBL were reported in E-ESBL in cattle. *E. coli* and *K. pneumoniae* were the species that harbour the genes and these are of faecal and clinical origin. CTX-M-3, CTX-M-14, CTX-M-15, CTX-M-17/18 and SHV-12 have already been described in humans in E-ESBLs ([@bib20]; [@bib55]).

Switzerland presented E-ESBL in cattle with CTX-M-1, CTX-M-14, CTX-M-15, CTX-M-117, CTX-M, TEM-186 and ND-ESBL ([@bib74], [@bib75]; [@bib177]; [@bib232]). They were reported in 3 species: *E. coli*, *C. youngae* and *E. cloacae*. All reports were of faecal origin, with the exception of 1 case of mastitis (CTX-M-14) ([@bib75]). E-ESBL of human origin have been reported to harbour CTX-M-1, CTX-M-14 and CTX-M-15 in Switzerland ([@bib76]).

CTX-M-1, CTX-M-15 and TEM-24 were described in E-ESBL in cattle in Italy. Reported in *K. pneumoniae* (mastitis) and *K. ozaenae* (faecal carriage). The three types of ESBL described in cattle, CTX-M-1, CTX-M-15 and TEM-24, have also been described in human clinical isolates ([@bib145]; [@bib168]).

Turkey is the second largest cattle producer in Europe and presented E-ESBL in cattle with CTX-M-1, CTX-M-3, CTX-M-15, SHV-5, SHV-12 and OXA-10 in *E. coli*, *C. freundii* and *C. brakii* of faecal origin ([@bib14]; [@bib120]; [@bib165]). CTX-M-1, CTX-M-3, CTX-M-15, SHV-5 and SHV-12 were reported in human clinical isolates in Turkish hospitals ([@bib83]; [@bib207]).

The Nordic countries have few reports and diversity of beta-lactamases, with E-ESBL in cattle harbouring CTX-M-1 in Denmark and Finland and CTX-M-1 and CTX-M-15 in Sweden all in *E. coli* and of intestinal origin ([@bib57]; [@bib116]; [@bib161]). When analysed the description in E-ESBL of human origin, CTX-M-1 has been described in Denmark, Finland and Sweden and CTX-M-15 in Sweden ([@bib27]; [@bib67]; [@bib2]).

In the Iberian Peninsula, Spain and Portugal also presented E-ESBL in cattle, with descriptions on Spain of CTX-M-1, CTX-M-55 and ND-ESBL and in Portugal of CTX-M-1 and CTX-M-32 ([@bib26]; [@bib95]; [@bib174]). The descriptions in both countries were in *E. coli*, but in Spain they were of faecal and clinical origin and in Portugal only faecal. CTX-M-1 has already been described in E- ESBL in human in Spain and CTX-M-1 and CTX-M-32 in Portugal ([@bib65]; [@bib151]).

CTX-M-1 was described in Hungary, Czech Republic and Slovakia and CTX-M-14 in Belgium in E-ESBL in cattle. All in *E. coli* and with faecal and clinical origins ([@bib53]; [@bib117]; [@bib163]; [@bib212]). In E-ESBL of human origin, CTX-M-1 has already been reported in Hungary, Czech Republic and CTX-M-14 in Belgium ([@bib53]; [@bib58]; [@bib181]).

4. North America {#sec4}
================

In North America only 2 countries registered E-ESBL description in cattle, Canada and the United States, the last one being the world\'s largest cattle producer ([@bib214]). CTX-M-15, CTX-M-32 and CTX-M-65 were the only beta-lactamases described in both countries, the [Figure 3](#fig3){ref-type="fig"} shows the complete described ESBL from cattle in the North America ([@bib38]; [@bib139]; [@bib172]; [@bib208]).Figure 3Illustrative map of North America with the countries with description of E-ESBL in cattle and the diversity of beta-lactamases presented.Figure 3

In the United States there were described in E-ESBL in cattle the CTX-M-1, CTX-M-9, CTX-M-14, CTX-M-15, CTX-M-27, CTX-M-32, CTX-M-65, CTX-M-79, CTX-M, SHV and TEM. E-ESBL of clinical and faecal origin in *E. coli*, *Salmonella* enteric and *Salmonella* spp ([@bib8]; [@bib45]; [@bib70]; [@bib139]; [@bib141]; [@bib172]; [@bib208]; [@bib222]). CTX-M- 1, CTX-M-14, CTX-M-15 and CTX-M-65 were reported in E-ESBL isolates from humans ([@bib34]; [@bib122]; [@bib208]; [@bib219]).

CTX-M-1, CTX-M-2, CTX-M-14, CTX-M-15, CTX-M-24, CTX-M-27, CTX-M-32, CTX-M-55, CTX-M-61, CTX-M-65, CTX-M-115, CTX-M-172, CTX-M, SHV-2 and ND-ESBL were described in E-ESBL in cattle in Canada, which was the country where the largest variety of CTX-M\'s types were described ([@bib15]; [@bib38]; [@bib129]). All E-ESBLs were *E. coli* of faecal origin. In E-ESBL of human origin in Canada were detected similarly to cattle the CTX-M-2, CTX-M-15, CTX-M-24, CTX-M-27, CTX-M-55, CTX-M-65 and SHV-2 ([@bib47], [@bib48]; [@bib166]; [@bib170]).

5. South America {#sec5}
================

In South America E-ESBL is still poorly described, being few and incomplete, from the molecular point of view, the reports of E-ESBL in cattle in the countries of this continent. Only Brazil, Chile and Peru present reports of E-ESBL in cattle. [Figure 4](#fig4){ref-type="fig"} shows what E-ESBL has already been described in these countries.Figure 4Map of South America illustrating the countries with description of E-ESBL in cattle and the diversity of beta-lactamases presented.Figure 4

Brazil is the world\'s second largest cattle producer and the world\'s second largest exporter of cattle ([@bib214]). The presence of E-ESBL in cattle with CTX-M-2, CTX-M-15, CTX-M, SHV and ND-ESBL has already been described in the country ([@bib150]; [@bib162]; [@bib187]; [@bib188]). Originated from mastitis or with faecal origin in *E. coli* and *K. pneumoniae*. There are several reports in human clinical E-ESBL of CTX-M-2, CTX-M-15, CTX-M and SHV in Brazil ([@bib186]).

Chile and Peru describe the presence of E-ESBL, but not described the enzymes responsible for ESBL phenotype. These reports were in *E. coli* in mastitis in Chile and in *E. coli* and *E. cloacae* of faecal origin in Peru ([@bib80]; [@bib136]). Both countries have reports of E-ESBL in humans ([@bib37]; [@bib94]).

6. Asia {#sec6}
=======

The second continent with the highest number of countries reporting E-ESBL in cattle is Asia, which shows description of E-ESBL in 13 countries (China, Hong Kong, India, Indonesia, Iran, Israel, Japan, Lebanon, Malaysia, Saudi Arabia, South Korea, Thailand and Taiwan), highlighting China and India which are the fourth and fifth largest cattle producers in the world ([@bib7]; [@bib12]; [@bib19]; [@bib50]; [@bib91]; [@bib97]; [@bib101]; [@bib110]; [@bib119]; [@bib153]; [@bib201]; [@bib202]; [@bib206]). They have different roles in the import and export scenario, as India is the world\'s largest exporter of cattle and China the largest importer, since its internal production is not sufficient for internal consumption ([@bib214]). [Figure 5](#fig5){ref-type="fig"} shows the countries and the diversity of beta-lactamases found in each of them.Figure 5Asia illustrative map of countries with description of E-ESBL in cattle and the diversity of beta-lactamases presented.Figure 5

China presents a description of E-ESBL in cattle harbouring CTX-M-1, CTX-M-3, CTX-M-14, CTX-M-15, CTX-M-17, CTX-M-28, CTX-M-55, CTX-M-65, CTX-M-88, CTX-M-98, CTX-M-102, CTX-M-103, CTX-M-123, CTX-M and SHV-12. All descriptions were in *E. coli* and faecal origin and mastitis ([@bib12]; [@bib226]; [@bib229]). CTX-M-3, CTX-M-14, CTX-M-15, CTX-M-55 and SHV-12 were described isolated from E-ESBL of human origin in China ([@bib106]; [@bib210]).

In India CTX-M-15, CTX-M-63, CTX-M, SHV-180, SHV and TEM in E-ESBL from cattle have already been described. Faecal origin and mastitis, being detected in *E. coli* and *K. pneumoniae* ([@bib22]; [@bib44]; [@bib119]). The presence of CTX-M-15 and SHV in E-ESBL in India has been reported in humans ([@bib92]).

Japan and South Korea, the 3rd and 4th largest world importers of cattle, presented E-ESBL in cattle, respectively, with CTX-M-1, CTX-M-2, CTX-M-14, CTX-M-15 and SHV-11 and CTX-M-1, CTX-M-3, CTX-M-14, CTX-M-15, CTX-M-32, and CTX-M. These were detected in faecal E-ESBL and clinical in the animals and in Japan in *E. coli*, *K. pneumonia*, *K. oxytoca*, *C. freundii*, *C. koseri*, *E. cloacae* and *E. aerogenes* and in South Korea only in *E. coli* ([@bib153], [@bib154]; [@bib192]; [@bib204], [@bib205]; [@bib206]*)*. In Japan CTX-M-14, CTX-M-15 and SHV-11 have been described in E-ESBL of human origin ([@bib121]; [@bib185]). The CTX-M-3, CTX-M-14, CTX-M-15 and CTX-M-32 beta-lactamases have already been described in E-ESBL of human origin in South Korea ([@bib3]).

Hong Kong and Taiwan presented an E-ESBL profile in cattle only with reports of beta-lactamases of the CTX-M type. Hong Kong with CTX-M-3, CTX-M-14, CTX-M-28, CTX-M-55, CTX-M-98, CTX-M-123, CTX-M-132 and CTX-M ([@bib56]; [@bib98], [@bib100], [@bib101]). Taiwan already has CTX-M-14, CTX-M-15 and CTX-M-55 ([@bib201]). All in *E. coli* of faecal origin and mastitis. In Hong Kong the E-ESBL description of human origin has been reported well for CTX-M-14 and in Taiwan for CTX-M-14 and CTX-M-15 ([@bib225]; [@bib227]).

Indonesia, Malaysia, and Thailand reported E-ESBL in cattle, respectively, for CTX-M-1 and CTX-M-9; CTX-M; and TEM and ND-ESBL. All in *E. coli* of origin in mastitis or faecal ([@bib97]; [@bib110]; [@bib202]). In humans, reports of E-ESBL have been described for CTX-M-1 in Indonesia, CTX-M in Malaysia and ND-ESBL in Thailand ([@bib17]; [@bib99]; [@bib115]).

In the Middle East region there is a description of E-ESBL in cattle in Saudi Arabia (CTX-M), Iran (ND-ESBL), Israel (CTX-M-15, CTX-M, SHV and ND-ESBL) and in Lebanon (CTX-M-15). They were identified in *E. coli* and *K. pneumoniae* in faecal samples ([@bib7]; [@bib19]; [@bib50]; [@bib91]; [@bib125]). All E-ESBL profiles in cattle described above in these countries are also found described in humans ([@bib21]; [@bib35]; [@bib90]; [@bib143]).

7. Africa {#sec7}
=========

In Africa, only 6 countries presented reports of E-ESBL in cattle. They were Egypt, Madagascar, Nigeria, South Africa, Tanzania and Tunisia ([@bib24]; [@bib72]; [@bib109]; [@bib140]; [@bib156]; [@bib183]; [@bib190]). There are not numerous nor descriptive reports on this continent. They are also not very prominent countries within the world economic cattle cycle, highlighting only Egypt which is the 8th biggest importer of cattle in the world ([@bib214]). [Figure 6](#fig6){ref-type="fig"} shows the countries with E-ESBL reported in cattle and what beta-lactamase type has been described in them.Figure 6Map of Africa illustrating the countries with description of E-ESBL in cattle and the diversity of beta-lactamases presented.Figure 6

In Egypt E-ESBL was described in cattle harbouring CTX-M-9, CTX-M-15, SHV-12, SHV-28, TEM and OXA-30. Described in *E. coli*, *K. pneumoniae*, *K. oxytoca*, *E. cloacae* and *S. marcescens* of faecal origin and mastitis ([@bib9]; [@bib24]). There are reports in human E-ESBL also with CTX-M-9, CTX-M-15 and SHV-12 ([@bib64]; [@bib87]; [@bib149]).

South Africa (CTX-M), Madagascar (CTX-M-15), Nigeria (CTX-M and ND-ESBL), Tanzania (CTX-M-15) and Tunisia (CTX-M-15) also presented reports of E-ESBL in cattle. The reports were *E. coli*, *Klebsiella* sp, *Salmonella* sp, *P. mirabilis*, *P. vulgaris*, *Providencia* sp e *Shigella* spp ([@bib72]; [@bib109]; [@bib152]; [@bib156]; [@bib183]; [@bib190]). In all countries the origin was faecal (except Tunisia, with mastitis also). All types of descriptions presented in these 5 countries for E-ESBL in cattle also present reports in humans ([@bib4]; [@bib108]; [@bib134]; [@bib158]).

8. Oceania {#sec8}
==========

In Oceania as one might imagine, due to its size and number of countries, there exist few reports of E-ESBL in cattle production. The only country with reports is Australia, which is the 6th largest world producer country and the 3rd biggest exporter ([@bib214]). [Figure 7](#fig7){ref-type="fig"} shows the countries with E-ESBL description in cattle and what ESBL type has been described in them.Figure 7Map of Oceania illustrating countries with description of E-ESBL in cattle and the diversity of beta-lactamases presented.Figure 7

Australia presented a description of CTX-M-9 and CTX-M-14 in E-ESBL in cattle. The description was carried out in clinical isolated and in *E. coli* and in *S.* enterica ([@bib5]; [@bib197])*.* Both variants, CTX-M-9 and CTX-M-14, have already been described in human clinical isolates in Australia ([@bib231]).

9. Conclusion {#sec9}
=============

E-ESBL are a threat to human health and are now scattered around the world in intestinal colonization and clinical processes of cattle in Europe, the Americas, Asia, Africa and Oceania. These are described in 6 of the 7 major world cattle producers and certainly these E-ESBLs are contributing to the circulation of these and the ESBL genes through the ecosystems. A circulation that does not only concern the internal level of each country, since the circulation trade of cattle and their derivatives between countries is increasing, with E-ESBL being found in the animals of the world 5 largest meat exporters.

Further studies in the various areas of each country, as well as in other countries without data, are necessary for a better understanding of the presence and circulation of these E- ESBL through cattle and the food chain to assist in the implementation of measures to help in the surveillance and control of the E-ESBL dissemination and propagation.
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